CFO Buys $25K in Warrants as Part of Recent Private Placement

summarizeSummary

Aprea Therapeutics' CFO, John P. Hamill, purchased $24,999 worth of pre-funded and common warrants, participating in the company's recently announced $30 million private placement.

check_boxKey Events

• CFO Investment

  John P. Hamill, the company's CFO, acquired $24,999 worth of pre-funded and common warrants on March 31, 2026.

• Participation in Private Placement

  This purchase was part of the $30 million private placement announced on March 30, 2026, which significantly extended the company's cash runway and addressed prior financial viability concerns.

• Insider Confidence Signal

  The CFO's personal investment, representing 0.31% of the company's market capitalization, demonstrates conviction in the company's prospects following a crucial financing round.

auto_awesomeAnalysis

This Form 4 filing details the personal investment of Aprea Therapeutics' CFO, John P. Hamill, in the company's recent oversubscribed $30 million private placement. His purchase of nearly $25,000 in pre-funded and common warrants, representing 0.31% of the company's market capitalization, signals strong insider confidence following a critical financing event that addressed the company's going concern risk. This insider buy reinforces the positive sentiment around the successful capital raise.